ENX-102 clinical trials
Also written ENX-102.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2023
How each study uses ENX-102 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ENX-102
- 3
Studies by the year they started
3 studies that test it; most in 2023 (1)
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Engrail Therapeutics INC (3)
Studies
Open first, then newest update. How each study uses ENX-102 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- ENCALM: A Study of ENX-102 as a Monotherapy Treatment in Patients With Generalized Anxiety DisorderCompletedPhase 2Engrail Therapeutics INCNCT05749055Written as ENX-102
- A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety DisorderCompletedPhase 2Engrail Therapeutics INCNCT07193563Written as ENX-102
- A Dose-Response Safety Study of ENX-102 in Patients With GADCompletedPhase 2Engrail Therapeutics INCNCT06653296Written as ENX-102